Wealth Enhancement Advisory Services LLC Boosts Holdings in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Wealth Enhancement Advisory Services LLC significantly increased its holdings in DENTSPLY SIRONA by 224.6%, acquiring an additional 121,047 shares, bringing its total to 174,950 shares worth approximately $2.9 million.
• The company's recent earnings report showed $0.52 earnings per share for the quarter, beating expectations, although revenues decreased by 4.9% year-over-year.
• DENTSPLY SIRONA announced a quarterly dividend of $0.16 per share, yielding 5.1%, with the ex-dividend date set for September 26.

Wealth Enhancement Advisory Services LLC increased its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 224.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 174,950 shares of the medical instruments supplier's stock after buying an additional 121,047 shares during the quarter. Wealth Enhancement Advisory Services LLC owned 0.09% of DENTSPLY SIRONA worth $2,916,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sivia Capital Partners LLC bought a new stake in shares of DENTSPLY SIRONA during the second quarter worth $389,000. Pallas Capital Advisors LLC lifted its stake in DENTSPLY SIRONA by 83.2% during the second quarter. Pallas Capital Advisors LLC now owns 82,171 shares of the medical instruments supplier's stock worth $1,305,000 after purchasing an additional 37,306 shares during the last quarter. Krilogy Financial LLC acquired a new position in shares of DENTSPLY SIRONA in the second quarter valued at approximately $336,000. MassMutual Private Wealth & Trust FSB increased its position in shares of DENTSPLY SIRONA by 160.2% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 2,805 shares of the medical instruments supplier's stock valued at $45,000 after buying an additional 1,727 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in DENTSPLY SIRONA by 142.4% in the second quarter. Parallel Advisors LLC now owns 14,910 shares of the medical instruments supplier's stock valued at $237,000 after purchasing an additional 8,760 shares during the last quarter. Institutional investors own 95.70% of the company's stock.

DENTSPLY SIRONA Trading Up 1.1%

Shares of DENTSPLY SIRONA stock opened at $12.50 on Friday. DENTSPLY SIRONA Inc. has a fifty-two week low of $12.14 and a fifty-two week high of $27.44. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -2.64, a price-to-earnings-growth ratio of 0.78 and a beta of 0.96. The company has a quick ratio of 1.11, a current ratio of 1.69 and a debt-to-equity ratio of 1.13. The business has a fifty day simple moving average of $14.14 and a 200-day simple moving average of $14.81.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.02. The firm had revenue of $936.00 million during the quarter, compared to the consensus estimate of $929.67 million. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The firm's revenue for the quarter was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.49 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. On average, equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 10th. Shareholders of record on Friday, September 26th will be paid a dividend of $0.16 per share. The ex-dividend date is Friday, September 26th. This represents a $0.64 annualized dividend and a yield of 5.1%. DENTSPLY SIRONA's dividend payout ratio is presently -13.50%.

Wall Street Analyst Weigh In

XRAY has been the topic of several research reports. Stifel Nicolaus cut their price objective on DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating on the stock in a research note on Friday, August 8th. Barrington Research cut their target price on DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Wall Street Zen raised DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research report on Friday. Wells Fargo & Company decreased their target price on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Friday, August 8th. Finally, UBS Group cut their target price on shares of DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Two research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $18.64.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.